Refractory Pediatric Eczema: A Week of Wet Wraps Against a Six-Week Wait for a Biologic
He is old enough now to be embarrassed by the scratching in front of his team. The intensive option works this week; the durable one needs six weeks of paperwork to even start.
He used to be the kid who signed up for every extracurricular his parents offered; this fall he has started asking to skip soccer practice, and when his mother pressed him about it he admitted he didn't want his teammates to see him scratching. His eczema now covers close to 40% of his body, with the thick, leathery lichenification at both elbow and knee creases that comes from a rash that has been actively inflamed for a long time, and he has already failed a potent topical steroid course and eight weeks of tacrolimus ointment layered on top of it.
The clean next step on paper is dupilumab, now approved down to six months of age and backed by pediatric trial data from LIBERTY AD PRESCHOOL, which enrolled children from six months to five years — at five he sits at the very top of that studied band, and the 6-to-11-year LIBERTY AD PEDS data will describe him better next year than any of it does today. The problem the paper doesn't solve is time: his family's insurance plan quotes four to six weeks for prior authorization on a pediatric biologic, and nothing about that timeline moves faster because his skin is bad today. Wet-wrap therapy — diluted topical steroid applied under a damp layer of wrapping, then a dry layer over that, typically for several days to a week — has a real evidence base for producing meaningful improvement inside that same week, in children whose disease looks exactly like his.
He is otherwise a healthy child, growing normally, with no other chronic medical conditions and no history of skin infection despite the extent of his eczema — a genuinely reassuring baseline given how much lichenified, chronically inflamed skin he's carrying right now, since broken, weeping skin at this scale is exactly where a secondary bacterial infection tends to take hold. His parents have already rearranged their work schedules twice this year around dermatology visits, and his mother, a nurse herself, mentioned she has been applying the wet-wrap technique from memory on bad nights without quite getting the layering right, which is itself a small argument for a properly supervised course rather than continuing an improvised version of the same idea.
What actually helps him this week versus in six weeks
I want to start the prior authorization today, not after we've tried something else first. Every week we spend on another topical strategy before starting that process is a week added to however long the paperwork already takes.
I'm not arguing against starting the paperwork today — start it this afternoon. But that does nothing for him this week, and this week is when he's refusing to go to practice. Wet-wrap therapy has real evidence behind it for exactly this picture — González-López's 2017 systematic review and meta-analysis is the one to cite: refractory, lichenified AD, days rather than weeks to real improvement.
It's intensive for the family — damp wraps, then dry wraps, usually for several nights running — but it's not a competing treatment plan against dupilumab. It's the only thing that can do anything for him in the window the paperwork is going to take regardless.
That framing I can work with — run both in parallel, not one instead of the other. My only real concern is making sure a week of wet wraps that goes well doesn't become a reason to quietly let the authorization slide once he looks better.
Agreed: begin the wet-wrap protocol tonight for five to seven nights, and submit the dupilumab prior authorization the same day rather than waiting to see how the wraps perform first.
A specific follow-up point was set explicitly, not left as an assumption: if the wraps produce enough improvement that the family is tempted to let the authorization lapse, the visible improvement is not evidence the underlying disease has changed — it is the expected, temporary effect of an occlusive topical course, and the biologic process continues regardless of how good this week looks.